[Asia Economy Reporter Chunhee Lee] Celltrion announced on the 4th that it has launched its self-developed intestinal disease management service application (app) 'GwaJangNim Care' and is seeking synergy with its own biosimilar product lineup.
Celltrion explained that this app launch is the result of forming a dedicated team within the R&D organization since 2019 to review various patient support programs and potential business models utilizing digital devices. GwaJangNim Care is a mobile app for effective disease management of irritable bowel syndrome (IBS) patients. It features ▲ recording patient conditions such as disease symptoms ▲ diet and medication records ▲ providing disease trend reports based on a database ▲ expert consultations. It is currently available in both iOS and Android versions.
Celltrion plans to actively engage in disease management for IBS and inflammatory bowel disease (IBD) patients by expanding the use of self-developed apps including GwaJangNim Care. Additionally, through future service enhancement and data accumulation, it is considering expanding the business into various business models. In particular, it will focus on exploring services that can create synergy with the Remsima product line (intravenous (IV) and subcutaneous (SC) formulations), Uplyma, and other autoimmune disease treatments.
A Celltrion representative said, “Starting with the launch of this new app, we plan to prepare various measures that provide convenience to patients and healthcare professionals using digital devices,” adding, “We will continue to advance our business to maximize synergy with Celltrion’s antibody biosimilar product lineup.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
